Cost-effectiveness of a 24-month fixed duration of venetoclax in combination with rituximab in relapsed or refractory chronic lymphocytic leukemia in the United States Meeting Abstract


Authors: Huntington, S. F.; Strunz-McKendry, T.; Masaquel, A. S.; Shapouri, S.; Sail, K.; Durno, N.; Mato, A.
Abstract Title: Cost-effectiveness of a 24-month fixed duration of venetoclax in combination with rituximab in relapsed or refractory chronic lymphocytic leukemia in the United States
Meeting Title: ISPOR 2019
Journal Title: Value in Health
Volume: 22
Issue: Suppl. 2
Meeting Dates: 2019 May 18-22
Meeting Location: New Orleans, LA
ISSN: 1098-3015
Publisher: Elsevier Science, Inc.  
Date Published: 2019-05-01
Start Page: S78
End Page: S79
Language: English
ACCESSION: WOS:000472670100208
DOI: 10.1016/j.jval.2019.04.246
PROVIDER: wos
Notes: Meeting Abstract: PCN122 -- Source: Wos
Altmetric Score
MSK Authors
  1. Anthony R Mato
    46 Mato